Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy

Terry J. Smith1,2* and Joseph A. M. J. L. Janssen3

1 Department of Ophthalmology and Visual Sciences, Division of Metabolism, Endocrinology, and Diabetes, University of Michigan Medical School, Ann Arbor, MI, USA, 2 Department of Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes, University of Michigan Medical School, Ann Arbor, MI, USA, 3 Department of Internal Medicine, Erasmus Medical Center, Division of Endocrinology, Rotterdam, Netherlands

The pathogenesis of orbital Graves’ disease (GD), a process known as thyroid-associated ophthalmopathy (TAO), remains incompletely understood. The thyrotropin receptor (TSHR) represents the central autoantigen involved in GD and has been proposed as the thyroid antigen shared with the orbit that could explain the infiltration of immune cells into tissues surrounding the eye. Another cell surface protein, insulin-like growth factor-I receptor (IGF-IR), has recently been proposed as a second antigen that participates in TAO by virtue of its interactions with anti-IGF-IR antibodies generated in GD, its apparent physical and functional complex formation with TSHR, and its necessary involvement in TSHR post-receptor signaling. The proposal that IGF-IR is involved in TAO has provoked substantial debate. Furthermore, several studies from different laboratory groups, each using different experimental models, have yielded conflicting results. In this article, we attempt to summarize the biological characteristics of IGF-IR and TSHR. We also review the evidence supporting and refuting the postulate that IGF-IR is a self-antigen in GD and that it plays a potentially important role in TAO. The putative involvement of IGF-IR in disease pathogenesis carries substantial clinical implications. Specifically, blocking this receptor with monoclonal antibodies can dramatically attenuate the induction by TSH and pathogenic antibodies generated in GD of proinflammatory genes in cultured orbital fibroblasts and fibrocytes. These cell types appear critical to the development of TAO. These observations have led to the conduct of a now-completed multicenter therapeutic trial of a fully human monoclonal anti-IGF-IR blocking antibody in moderate to severe, active TAO.

Keywords: autoimmune, insulin-like growth factor I receptor, thyrotropin receptor, Graves’ disease, hybrid receptor, antibodies, autoantibodies

INTRODUCTION

The mechanisms underlying Graves’ disease (GD) remain incompletely understood (1). Among the open questions is the basis for loss of immunological tolerance to the thyrotropin receptor (TSHR). Factors underpinning the orbital manifestations of GD, a process known as thyroid-associated ophthalmopathy (TAO), are even less well understood. The unambiguous identification of a pathogenic
IGF-IR and the insulin receptor (IR) belong to the family of ligand-activated, plasma membrane-bound tyrosine kinase receptors. Both receptors are widely expressed in many tissues (7). They exhibit substantial structural homology. Depending on which regions are compared, they share sequence identities varying from 41 to 84% (8). Nevertheless, they serve distinct physiological functions important disease-promoting role in TAO. We also review the proposed mechanisms through which the receptor might serve as a molecular conduit for transducing disease-related signaling initiated by IGF-IR itself and by TSHR. It is possible that IGF-IR might be effectively targeted as therapy for TAO.

**GENERAL CONCEPTS ABOUT THE IGF-IR**

IGF-IR activity while promoting MAPK signaling (22, 27). The roles played by β-arrestin-1 in IGF-IR resemble its functions in regulating the behavior of GPCRs. Thus the protein suppresses IGF-IR activity while promoting MAPK signaling (22, 27).

**GENERAL CONCEPTS ABOUT THE TSHR**

It has been more than 40 years since convincing evidence was put forward for a cell surface-displayed TSHR on thyroid epithelial cells (28). The TSHR gene was first cloned by Vassart and colleagues in 1989 (29). The encoding mRNA has been detected subsequently not only in thyroid tissue but also in multiple fatty depots in animals and human beings (30, 31). Its cognate ligand, TSH, is a glycoprotein hormone produced by thyrotrophs located in the anterior pituitary gland. TSHR plays a central role in the regulation of thyroid growth and function (32). More recently, the receptor was co-crystallized with anti-TSHR antibodies and its structure solved (33, 34). TSHR belongs to the family of rhodopsin-like GPCRs which also includes receptors for luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These proteins possess seven plasma membrane-spanning regions within the so called serpentine domain (35). Surface-displayed

autoantigen shared by the orbit and thyroid gland remains to be accomplished. TSHR is the most likely candidate by virtue of its established central role in mediating the hyperthyroidism associated with GD. It has been detected, albeit at very low levels, in the healthy orbit and at somewhat higher levels in orbital tissues during TAO (2). Thyroglobulin (Tg) is another antigen suspect because of its previously unexplained presence in the diseased orbit (3). The insulin-like growth factor-I receptor (IGF-IR) has joined the conversation. It appears to be overexpressed in GD in several cellular compartments (4). Insinuation of IGF-IR in TAO has ignited substantial debate among workers in the field of thyroid autoimmunity (5, 6). In this brief review, we attempt to present a balanced assessment of evidence both refuting and supporting the concept that IGF-IR plays an active and important disease-promoting role in TAO. We also review the proposed mechanisms through which the receptor might serve as a molecular conduit for transducing disease-related signaling initiated by IGF-IR itself and by TSHR. It is possible that IGF-IR might be effectively targeted as therapy for TAO.
TSHR exists as a multimeric structure (36). The extracellular region represents the amino-terminus containing a high-affinity TSH binding site. The unligated extracellular domain interacts as an inverse agonist with the serpentine domain. TSHR is encoded by a single gene and is synthesized as a single peptide chain that undergoes cleavage into “A” and “B” subunits (37). These are then linked by a disulfide bond. Unlike the receptors for LH and FSH, the extracellular TSHR domain undergoes metalloproteinase-dependent cleavage (38). Some debate exists as to whether the cleavage occurs at the same precise site(s) on the protein and whether the resulting C-peptide sequence is invariant. The specific protease responsible for this cleavage has yet to be identified (39). Evidence has been introduced supporting the concept that this cleaved receptor fragment is shed and provokes the generation of thyroid-stimulating IgGs (TSI) (40). Some authors have expressed the view that the cleaved fragments of TSHR are released into thyroid lymphatics draining into lymph nodes where they are processed by antigen-presenting cells through interactions with mannose receptors (38). TSIs are responsible for the hyperthyroidism associated with GD (40). But not all anti-TSHR antibodies are stimulatory. Some block binding of TSH to the receptor (33) while others are viewed as “neutral.”

The exact mechanisms involved in the activation of TSHR by either TSH or TSIs remain uncertain although the ligand binding epitopes have been localized (33, 34). Interactions between the different classes of anti-TSHR antibodies and the receptor have also been characterized (41). Signaling downstream from TSHR is complex and involves several pathways that cross talk in patterns that determine the ultimate genes targeted for activation (42–44). Similar but non-identical downstream signaling occurs following TSH and TSI binding to TSHR (45).

**EXTRA-THYROIDAL TSHR**

Detection of TSHR expression peripheral to the thyroid gland has implicated the protein in an expanding array of biological functions. Particular focus on extra-thyroidal TSHR has involved studies examining the pathogenesis of TAO. Feliciello et al. detected TSHR mRNA in orbital tissues from healthy donors and those with GD (2). TSH promotes lipolysis in rodents and human beings (46, 47). With more advanced techniques of detection, TSHR has been identified, albeit at a very low level, in many fatty and non-adipose tissues (48). The receptor has recently been insinuated in the regulation of bone metabolism (49).

**EVIDENCE FOR INTERACTIONS BETWEEN IGF-IR AND TSHR**

Accumulating evidence supports the general concept that dissimilar receptor proteins can interact by forming complex signaling partnerships. Recently, Girnita et al. suggested that IGF-IR forms functional hybrids with GPCRs (27). These hybrids utilize components of GPCR signaling and can thus activate pathways conventionally used by GPCRs (27). Multimeric molecular structures of these receptor complexes may help explain the functional interplay that appears to occur between IGF-IR and TSHR pathways. A relationship between IGF-I and TSH signaling was first recognized in 1986 by Ingbar and colleagues (50). They demonstrated that IGF-I could either enhance or antagonize the actions of TSH in cultured thyroid epithelial cells. For instance, IGF-I facilitates the actions of TSH on FRTL-5 cell proliferation while attenuating its induction of sodium/iodide symporter, interactions mediated through PI3 kinase (51). A synergy between the two factors was further demonstrated in the induction of 1, 2-diacylglycerol production in rat thyroid epithelium. In thyroid, the mitogenic activity of IGF-I can be potentiated by TSH (52, 53). TSH induces IRS-2 monoubiquitination in cultured thyroid cells, thereby enhancing IGF-I signaling and mitogenic activity. Both TSH and IGF-I enhance the nuclear content of β-catenin and thus promote Wnt-dependent thyroid epithelial proliferation (54). Conditional knock-out of IGF-IR in thyroid tissue results in increased serum TSH levels and lower serum thyroxine concentrations (55). This profile of circulating hormones suggests relative TSHR insensitivity. In contrast, over-expression of IGF-IR in thyroid amplifies the action of TSH and exagarates its impact on the synthesis of thyroid hormones (56). We hypothesize that a similar potentiating mechanism might apply following TSHR stimulation by circulating TSI. Further studies will be required to determine whether such a mechanism might underlie the results found in some actions of TSI in the pathogenesis of TAO.

It was uncertain how the two pathways might cross talk at the target cellular level until Tsui and colleagues reported that TSHR and IGF-IR appear to interact directly by forming a protein complex (57). Evidence for these TSHR/IGF-IR complexes was found in orbital fibroblasts and thyroid epithelium utilizing several strategies including co-localization studies with confocal microscopy and co-immunoprecipitation assays. Tsui et al. further demonstrated that a monoclonal blocking antibody directed against IGF-IR could attenuate activation of Erk1/2 by IGF-I, rhTSH, and IgG from patients with GD (57). This report unambiguously demonstrated the functional interdependence of TSHR and IGF-IR and strongly suggested that IGF-IR was trans-activated by TSHR. It was followed by several papers confirming (58) and in some cases extending (59, 60) these observations. Evidence for bidirectional crosstalk between the two receptors was demonstrated in another study in orbital fibroblasts (60). IGF-I and TSH were shown to act synergistically in that study by inducing HA production in orbital fibroblasts. Another recent paper contained evidence that inhibiting PI3 kinase and mTOR could attenuate HA accumulation upregulation mediated by these receptors (61). Unfortunately, cultures were exposed to the small molecule inhibitors for many days, inviting criticism of the study design used where conclusions were drawn based on findings that may have been non-specific. Another recent report demonstrated dependence on TSHR in TSHR knock-out mice of IGF-IR protein distribution and levels (62).

**EVIDENCE FOR INVOLVEMENT OF IGF-IR IN TAO**

Whether a specific autoantigen(s) shared by the orbit and thyroid participates in the pathogenesis of TAO remains an open
question. To our knowledge, demonstration of antigen-specific T cells among those lymphocytes infiltrating the orbit has yet to be unambiguously accomplished. One of the earliest investigators to explore the issue of an ectopically expressed thyroid antigen in the orbit was Kriss (3). He and his colleagues detected Tg in the TAO orbit using thyroidolymphography over four decades ago. More recent studies have substantiated this earlier work (63). Anti-Tg antibodies are commonly detected in thyroid autoimmunity including a substantial proportion of those individuals with GD; however, it is unclear how Tg or the antibodies directed against this protein might play an active role in TAO.

The IGF-I pathway was first implicated in TAO by Weightman et al. (64) who detected immunoglobulins in the sera of individuals with TAO that could displace binding of radiolabeled IGF-I from orbital fibroblast monolayers. This important study was the first to question whether antibodies directed against an IGF-I binding site might be present in these patients. Later studies from Pritchard et al. (65, 66) reported similar results and identified the binding site on orbital fibroblasts as IGF-IR. Their studies indicated that GD-IgG and IGF-I recognize a common binding site. These later studies also revealed that circulating IgGs in GD could induce chemokine expression in TAO orbital fibroblasts, indicating that at least some of these antibodies were biologically active. Pritchard et al. mapped the critical signaling downstream from IGF-IR to the FRAP/mTor/p70s6k pathway. They further demonstrated that the induction of IL-16 and RANTES was inhibited by rapamycin and by transfecting cells with a dominant negative IGF-IR (65, 66). The report also provided evidence for IGF-IR over-expression in these cells when compared to the levels of the receptor in orbital fibroblasts from healthy tissue.

ARE STIMULATORY ANTI-IGF-IR ANTIBODIES DISTINCT FROM TSI?

Reports from Pritchard et al. (65, 66) and Smith and Hoa (67) suggested that IgGs circulating in patients with GD can activate orbital fibroblasts have proven to be controversial (5, 6). The debate rests on whether activating antibodies differing from those against TSHR (i.e., TSI) and instead directly targeting IGF-IR are responsible for the upregulation of cytokine expression and hyaluronan production in orbital fibroblasts (65–67). A major barrier to our quest for the definitive answer derives from an inability to distinguish antibodies that activate IGF-IR from those that merely bind the receptor but fail to initiate signaling. Among the strongest evidence that anti-IGF-IR antibodies are generated in GD are the observations of Weightman et al. (64) and Pritchard et al. (65) demonstrating that GD-IgGs displace IGF-I binding to orbital fibroblasts. More recently, TSHR A-subunit plasmid DNA immunization of mice was shown to result in generation of anti-IGF-IR antibodies (68). Those studies were unable to detect any additional effects of co-immunization with TSHR and IGF-1Rα plasmids on the animal phenotype (68). Thus none of these reports provides insight into whether the anti-IGF-IR antibodies, distinct from TSI, can activate the receptor. Some workers in the field attribute activities of GD-Ig to TSIIs rather than IgGs targeting IGF-IR; however, subsequent studies by Pritchard et al. may provide some guidance (69). They demonstrated similar cytokine-inducing activity in synovial fibroblasts from patients with rheumatoid arthritis (RA) when challenged by RA-IgG (69). Their findings indicate that disease-specific IgGs apart from TSI are likely driving these inductions.

More recent studies examining whether activating anti-IGF-IR antibodies are generated in GD have yielded disparate results. Experiments conducted in undifferentiated orbital fibroblasts treated with rhTSH or GD-IgG failed to generate increased levels of HA (70). In contrast, once differentiated into adipocytes, these fibroblasts responded to both (71). Varewijick and colleagues (72) have detected activating anti-IGF-IR antibodies in subsets of patients with GD. They monitored the phosphorylation of multiple tyrosine residues of IGF-IR as the primary read-out for assessing IGF-IR activity (72). In contrast, Minich et al. (73) were unable to distinguish between low levels of anti-IGF-IR IgG activity in healthy controls and those with GD. Their assay was limited to detecting phosphorylation of a single adjacent pair of tyrosine residues (Tyr 1165/1166). They quantified the titer of IGF-IR autoantibodies but their assay was incapable of discriminating between activating and non-activating antibodies. Furthermore, their estimates of the lower limits of antibody titers were based on arithmetic arguments rather than on empirical observations. Another potentially confounding limitation of their study was the likely insensitivity of their assay to low-affinity antibodies. Moreover, effects of stimulating antibodies frequently occur within a narrow concentration range (74) and their studies did not investigate the impact of higher and lower antibody titers. In sum, the conclusions drawn by Minich et al. appear to ignore the likely complex relationship between circulating antibody titers and the magnitude of their biological effects.

Krieger et al. reported an induction by GD-IgG of hyaluronan release from orbital fibroblasts despite an absence of IGF-IR autophosphorylation (59). The authors argued that this scenario rules against an activation of IGF-IR occurring during this action of GD-IgG. They concluded that the actions of GD-IgG must, therefore, be initiated by TSHR rather than through direct interactions with IGF-IR. Yet the authors provided apparently contradictory evidence for receptor activation by demonstrating that the specific IGF-IR tyrosine kinase inhibitor, linsitinib, blocks induction by GD-IgG of hyaluronan production. Thus, we interpret their findings as strongly suggesting that the Western blot assay they used for monitoring IGF-IR phosphorylation failed to detect what might have been low-level but physiologically important receptor activation.

Factors potentially underlying these divergent results include the wide array of assays used, differing target cell types, and the culture conditions used. With regard to culture media, lot to lot variability of endogenous IGF-I, IGF-II, and IGFBP concentrations in the animal sera could alter the background read-out activities observed as well as the magnitude of cellular responses. Thus, it remains possible although unproven that two discrete antibodies generated in GD are at play in the pathogenesis of TAO. This theoretical construct involves one antibody directed at TSHR and the other at IGF-IR. Antibody-induced receptor activation might exhibit tissue specificity. Due to their relatively long half-life of greater than 1 week (52), antibody-dependent
FIGURE 1 | Theoretical mechanisms involved in the crosstalk between insulin-like growth factor-I receptor (IGF-IR) and thyrotropin receptor (TSHR) pathways.

(Continued)
activation of TSHR and IGF-IR could be relatively long-lived. It should be stressed that all currently available in vitro systems for assessing effects of antibodies on cultured cells may fail to mimic conditions existing in vivo. This could result in inaccurate estimates of the events occurring in situ within the orbit and potentially in thyroid tissue. In any event, assessment of anti-IGF-IR antibodies activating pathways conventionally used by GPCRs is unprecedented until now.

Most anti-IGF-IR antibodies target the ligand binding site and thus block the binding of endogenous ligands, thereby attenuating receptor activation (52). In contrast, antibodies binding elsewhere on the receptor may be more clinically relevant since they can induce receptor activation (74). Supporting this general concept is the observation that IR-stimulating antibodies activate the receptor by cross-linking subunits rather than by reacting to specific epitopes (74). Figures 1A–F summarize putative mechanisms involved in the pathogenesis of TAO. Agonists acting directly at both TSHR and IGF-IR may play roles in stimulating signaling pathways downstream from these receptors. Additional studies will be necessary to untangle what appear to be complex interactions that culminate in the disease.

**ULTIMATE TESTING OF THE HYPOTHESIS THAT IGF-IR PARTICIPATES IN TAO**

Addressing the question of whether IGF-IR plays an important pathogenic role in TAO and thereby carries potential for therapeutic targeting must await studies conducted in vivo. That concept has been tested very recently in a multicenter, placebo-controlled, double masked clinical trial of an IGF-IR blocking monoclonal antibody (teprotumumab or RV001) in active, moderate to severe TAO (http://clinicaltrials.gov/show/NCT01868997). The results of that prospective trial should shed new light on this as yet unresolved question.

**AUTHOR CONTRIBUTIONS**

TS reviewed the literature, drafted portions of the initial manuscript draft, amalgamated the portions of the paper generated by both authors, refined the text, and proof read the final draft. JJ reviewed the literature, drafted portions of the initial manuscript draft, refined the text, generated the theoretical model images, and proof read the final draft.

**ACKNOWLEDGMENTS**

The authors thank Darla Kroft for her expert help in manuscript preparation.

**FUNDING**

This work was supported in part by National Institutes of Health grants EY008976 and 5UM1AI110557, Center for Vision core grant EY007002 from the National Eye Institute, an unrestricted grant from Research to Prevent Blindness, and by the Bell Charitable Foundation.

**REFERENCES**

1. Smith TJ, Hegedus L. Graves’ disease. N Engl J Med (2016) 375:1552–65. doi:10.1056/NEJMra1510030
2. Feliciello A, Porcellini A, Ciullo I, Bonavolonta G, Avvedimento EV, Fenzi G. Expression of thyrotropin-receptor mRNA in healthy and Graves’ disease retro-orbital tissue. Lancet (1993) 342:337–8. doi:10.1016/0140-6736(93)91475-2
3. Kriss JP. Radioisotopic thyroidalymobraphy in patients with Graves’ disease. J Clin Endocrinol Metab (1970) 31:315–23. doi:10.1210/jcem-31-3-315
4. Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev (2010) 62:199–236. doi:10.1124/pr.109.002469
5. Wiersinga WM. Autoimmunity in Graves’ ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors? J Clin Endocrinol Metab (2011) 96:2386–94. doi:10.1210/jc.2011-0307
6. Smith TJ. Is IGF-1 receptor a target for autoantibody generation in Graves’ disease? J Clin Endocrinol Metab (2013) 98:515–8. doi:10.1210/jc.2013-1004
7. Abbott AM, Bueno R, Pedrini MT, Murray JM, Smith RJ. Insulin-like growth factor I receptor gene structure. J Biol Chem (1992) 267:10759–63.
8. Varewijck AJ, Janssen JA. Insulin and its analogues and their affinities for the IGF1 receptor. *Endocr Relat Cancer* (2012) 19:F63–75. doi:10.1530/ERC-12-0026.

9. Blakesley VA, Scringemour A, Esposito D, Le Roith D. Signalizing via the insulin-like growth factor-I receptor: does it differ from insulin receptor signaling? *Cytokine Growth Factor Rev* (1996) 7:153–9. doi:10.1016/1359-6101(96)00015-9.

10. Bondy CA, Underwood LE, Guler HP, Bach MA, Skarulis Smith and Janssen. *IGF-IR in Orbital Graves’ Disease*.

11. Froesch ER, Zapf J. Insulin-like growth factors and insulin: comparative aspects. *Diabetologia* (1985) 28:485–93. doi:10.1007/BF00201892.

12. Dupont J, LeRoith D. Insulin and insulin-like growth factor I receptors: similarities and differences in signal transduction. *Horm Res* (2001) 55(Suppl 2):22–6. doi:10.1159/000063469.

13. Laviola L, Natalicchio A, Giorgino F. The IGF-I signaling pathway. *Curr Pharm Des* (2007) 13:663–9. doi:10.2174/138161207780249146.

14. Bevan P. *Insulin signalling*.

15. King ER, Wong KK. Insulin-like growth factor: current concepts and new developments in cancer therapy. *Recent Pat Anticancer Drug Discov* (2012) 7:14–30. doi:10.2174/157488921279357930.

16. Slaaby R, Schaffer L, Lautrup-Larsen I, Andersen AS, Shaw AC, Mathiasen IS, et al. Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant. *J Biol Chem* (2006) 281:25869–74. doi:10.1074/jbc.M605189200.

17. Morshedi SA, Latif MR, Davies TF. Characterization of thyrotropin receptor mRNA expression in orbital as well as in extraorbital tissues. *Thyroid* (1998) 9:613–9. doi:10.1089/thy.1998.9.613.

18. Raefsema E, Veldhuis JD. Thyrotropin secretion patterns in health and disease. *Endocr Rev* (2013) 34:619–75. doi:10.1210/er.2012-1076.

19. Cechetto S, Scotti P, Michelie M, De Luca G, Marcocci C, Mazzocchi M, et al. Endogenous parathyroid hormone type 1 receptor (PTH1R) signaling through a non-canonical mechanism. *Endocr Rev* (2012) 33:79–117. doi:10.1210/er.2011-00148.

20. Ngirosoyo S, Lengua J, Kariuki A, Uwimana C, Anguile P, Onyango A, et al. Development of a rapid diagnostic test for the detection of TSH receptor antibodies in African children with thyrotoxicosis. *Mol Diagn Ther* (2014) 18:147–52. doi:10.1007/s11027-013-9269-0.

21. Wang X, Liang B, Zeng J, Chen Y, Qi L, Zuo G, et al. Expression and function of TSH receptor in fetal rat thyroid cells. *Thyroid* (2015) 25:238–45. doi:10.1089/thy.2014.0107.

22. Cirstea V, Mocanu A, Bratu M, Ilie S, Calinescu C, Dobre A, et al. The human thyrotropin receptor is expressed in the human thyroid gland and regulated by TSH. *Endocrinology* (2013) 154:2991–7. doi:10.1210/en.2012-2040.

23. Girnita L, Worrall C, Takahashi S, Seregard S, Girnita A. Something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation. *Cell Mol Life Sci* (2014) 71:2403–27. doi:10.1007/s00018-013-1514-y.
on the skeleton. *Proc Natl Acad Sci USA* (2013) 110:9891–6. doi:10.1073/pnas.1308336110

50. Cushing GW, Moses AC, Ingbar SH. Insulin-like growth factor I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves’-IgG. *Endocrinology* (1986) 119:940–2. doi:10.1210/endo-119-2-940

51. Garcia B, Santisteban P. PTK7 is involved in the IGF-I inhibition of TSH-induced sodium/iodide symporter gene expression. *Mol Endocrinol* (2002) 16:342–52. doi:10.1210/mend.16.2.0774

52. Bhaskar V, Goldfine ID, Bedinger DH, Lau A, Kuan HF, Gross LM, et al. Possible targets for nonimmunosuppressive therapy of Graves’ disease. *Mol Endocrinol* (2014) 28:681–95. doi:10.1210/me.2013-1377

53. Marie M, Chiovato L, Lisi S, Altea MA, Marcocci C, Pinchera A. Role of IGF-1 binding sites in thyroid associated ophthalmopathy. *Nat Commun* (2013) 6:6780. doi:10.1038/ncomms7780

54. Sastre-Peraona A, Santisteban P. Wnt-independent role of β-catenin in thyroid cell proliferation and differentiation. *Mol Endocrinol* (2014) 18:4397–405. doi:10.1210/me.2013-1377

55. Kumar S, Iyer S, Bauer H, Coenen M, Bahn RS. A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in Graves’ orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody. *J Clin Endocrinol Metab* (2012) 97:1681–7. doi:10.1210/jc.2011-2890

56. Krieger CC, Place RF, Bevilacqua C, Marcu-Samuels B, Abel BS, Skarulis MC, et al. TSH/IGF-1 receptor cross-talk in Graves’ ophthalmopathy pathogenesis. *J Clin Endocrinol Metab* (2016) 101:2340–7. doi:10.1210/jc.2016-1315

57. Tsui S, Naik V, Hoa N, Hwang CJ, Afiifiy NF, Hikim AS, et al. Evidence for an association between thyroid stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. *J Immunol* (2008) 181:1497–405. doi:10.4049/jimmunol.181.6.1497

58. Zhang L, Grennan-Jones F, Draham MS, Lane C, Morris D, Dayan CM, et al. Possible targets for nonimmunosuppressive therapy of Graves’ orbitopathy. *J Clin Endocrinol Metab* (2014) 99:E1183–90. doi:10.1210/jc.2013-3148

59. Atkins SJ, Lentz SI, Fernando R, Smith TJ. Disrupted TSH receptor expression and its requirement and goiter in transgenic mice overexpressing IGF-I and IGF-II receptor in the thyroid gland. *Endocrinology* (2001) 142:5131–9. doi:10.1210/endo.142.12.8534

60. Ock S, Ahn J, Lee SH, Kang H, Offermanas S, Ahn HY, et al. IGF-1 receptor deficiency in thyrocytes impairs thyroid hormone secretion and completely inhibits TSH-stimulated goiter. *FASEB J* (2013) 27:4899–908. doi:10.1096/fj.13-23181

61. Clement S, Refetoff S, Robaye B, Dumont JE, Schurmans S. Low TSH deficiency in thyrocytes impairs thyroid hormone production in nondifferentiated orbital fibroblasts of Graves’ ophthalmopathy patients. *Thyroid* (2010) 20:535–44. doi:10.1089/thy.2009.0447

62. Pritchard J, Tsui S, Horst N, Crukshank WW, Smith TJ. Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves’ disease, express high levels of IL-16 when treated with IgGs against insulin-like growth factor-1 receptor. *J Immunol* (2004) 173:3564–9. doi:10.4049/jimmunol.173.5.3564

63. Van Zeijl CJ, Fliers E, van Koppen CJ, Suruotseva OV, de Gooyter ME, Mouti MP, et al. Effects of thyrotropin and thyrotropin-receptor-stimulating Graves’ disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronic acid production in nondifferentiated orbital fibroblasts of Graves’ ophthalmopathy patients. *Thyroid* (2010) 20:535–44. doi:10.1089/thy.2009.0447

64. Pritchard J, Tsui S, Horst N, Crukshank WW, Smith TJ. Synovial fibroblasts from patients with Graves’ disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, IGF-1 receptor. *J Clin Endocrinol Metab* (2004) 89:5076–80. doi:10.1210/jc.2004-0716

65. Smith and Janssen

**Conflict of Interest Statement:** TS holds patents related to the detection of antibody-mediated inflammatory autoimmune disorders (US 8178304). No other potential conflict of interest relevant to this article was reported.

Copyright © 2017 Smith and Janssen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.